Page 113 - 《中国药房》2024年14期

[ 7 ] MALIK A H，ARONOW W S. Efficacy of sacubitril/val‐ revised in 2018[J]. Cardio Cerebrovasc Dis Prev Treat，
sartan in hypertension[J]. Am J Ther，2022，29（3）：e322- 2019，19（1）：1-44.
e333. [16] 上海慢性肾脏病早发现及规范化诊治与示范项目专家
[ 8 ] HUBERS S A，BROWN N J. Combined angiotensin re‐ 组，高翔，梅长林. 慢性肾脏病筛查 诊断及防治指南[J].
ceptor antagonism and neprilysin inhibition[J]. Circula‐ 中国实用内科杂志，2017，37（1）：28-34.
tion，2016，133（11）：1115-1124. Expert Group on Early Detection，Diagnosis and Treat‐
[ 9 ] MCDONAGH T A，METRA M，ADAMO M，et al. 2023 ment System Construction of Chronic Kidney Disease in
focused update of the 2021 ESC guidelines for the diagno‐ Shanghai，GAO X，MEI C L. Guideline for screening，diag-
sis and treatment of acute and chronic heart failure[J]. G nosis，prevention and treatment of chronic kidney disease
Ital Cardiol，2024，25（3）：202-213. [J]. Chin J Pract Intern Med，2017，37（1）：28-34.
[10] HEIDENREICH P A，BOZKURT B，AGUILAR D，et al. [17] ZHENG S H，ZHANG Y J，GU L，et al. Renal safety of
2022 AHA/ACC/HFSA guideline for the management of sacubitril/valsartan：a meta-analysis of randomized
heart failure：a report of the American College of Cardiolo- controlled trials[J]. J Cardiovasc Pharmacol，2023，81（2）：
gy/American Heart Association Joint Committee on clini‐ 93-103.
cal practice guidelines[J]. J Am Coll Cardiol，2022，79 [18] MANN D L，GIVERTZ M M，VADER J M，et al. Effect
（17）：e263-e421. of treatment with sacubitril/valsartan in patients with ad‐
[11] ZUO C C，LI X Y，FAN L L，et al. Effectiveness and vanced heart failure and reduced ejection fraction：a rando-
safety of sacubitril/valsartan for patients with hyperten‐ mized clinical trial[J]. JAMA Cardiol，2022，7（1）：17-25.
sion and heart failure in the real-world setting：a retrospec‐ [19] CAUSLAND F R M，LEFKOWITZ M P，CLAGGETT B，
tive study in China[J]. J Clin Pharm Ther，2022，47（10）： et al. Angiotensin-neprilysin inhibition and renal out‐
1539-1547. comes in heart failure with preserved ejection fraction[J].
[12] LEDWIDGE M，DODD J D，RYAN F，et al. Effect of Circulation，2020，142（13）：1236-1245.
sacubitril/valsartan vs valsartan on left atrial volume in [20] MCMURRAY J J，PACKER M，DESAI A S，et al.
patients with pre-heart failure with preserved ejection frac‐ Angiotensin-neprilysin inhibition versus enalapril in heart
tion：the PARABLE randomized clinical trial[J]. JAMA failure[J]. N Engl J Med，2014，371（11）：993-1004.
Cardiol，2023，8（4）：366-375. [21] SOLOMON S D，MCMURRAY J J V，ANAND I S，et al.
[13] KARIO K，RAKUGI H，YARIMIZU D，et al. Twenty- Angiotensin-neprilysin inhibition in heart failure with pre‐
four-hour blood pressure-lowering efficacy of sacubitril/ served ejection fraction[J]. N Engl J Med，2019，381（17）：
valsartan versus olmesartan in Japanese patients with 1609-1620.
essential hypertension based on nocturnal blood pressure [22] KIM Y S，BRAR S，D’ALBO N，et al. Five years of sacu‐
dipping status：a post hoc analysis of data from a randomi- bitril/valsartan：a safety analysis of randomized clinical trials
zed，double-blind multicenter study[J]. J Am Heart Assoc， and real-world pharmacovigilance[J]. Cardiovasc Drugs
2023，12（8）：e027612. Ther，2022，36（5）：915-924.
[14] NISHIO H，ISHII A，YAMADA H，et al. Sacubitril/valsar‐ [23] LAUDER L，MAHFOUD F，AZIZI M，et al. Hyperten‐
tan ameliorates renal tubulointerstitial injury through in‐ sion management in patients with cardiovascular comor‐
creasing renal plasma flow in a mouse model of type 2 dia‐ bidities[J]. Eur Heart J，2023，44（23）：2066-2077.
betes with aldosterone excess[J]. Nephrol Dial Transplant， [24] JIA R Y，ZHANG X J，XU Y Z，et al. Effect of sacubitril/
2023，38（11）：2517-2527. valsartan on renal function in patients with chronic kidney
[15] 《中国高血压防治指南》修订委员会. 中国高血压防治指 disease and heart failure with preserved ejection fraction：
南：2018 年修订版[J]. 心脑血管病防治，2019，19（1）： a real-world 12-week study[J]. Eur J Pharmacol，2022，
1-44. 928：175053.
Revision Committee of the Chinese Guidelines for the （收稿日期：2023-12-25 修回日期：2024-04-21）
Prevention and Treatment of Hypertension. Guidelines for （编辑：舒安琴）
prevention and treatment of hypertension in China：

中国药房 2024年第35卷第14期 China Pharmacy 2024 Vol. 35 No. 14 · 1775 ·